Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13591319 | 0.71 | CYP1A2 (0.56) | CYP1A2GABRA5GABRB2HSD17B10ALDH1A1 | |
| SCHEMBL1686855 | 0.65 | F2 (0.70) | HSD17B10ALDH1A1F2HPGD | |
| SCHEMBL2666129 | 0.65 | CYP1A2 (0.42) | CYP1A2GABRA5GABRB2HSD17B10ALDH1A1 | |
| SCHEMBL11241934 | 0.64 | AKR1B1 (0.45) | CYP1A2GABRA5GABRB2HSD17B10ALDH1A1 | |
| SCHEMBL27970992 | 0.64 | SLC6A3 (0.41) | ALDH1A1MEN1KMT2APTGDR2HPGD | |
| SCHEMBL16499267 | 0.64 | CYP1A2 (0.42) | CYP1A2GABRA5GABRB2HSD17B10ALDH1A1 | |
| SCHEMBL21631758 | 0.64 | AKR1B1 (0.41) | AKR1B1PTGDR2 | |
| SCHEMBL1582980 | 0.63 | GABRA5 (0.52) | CYP1A2GABRA5GABRB2HSD17B10ALDH1A1 | |
| SCHEMBL28497383 | 0.63 | HPSE (0.46) | GABRA5GABRB2HSD17B10ALDH1A1MEN1 | |
| SCHEMBL10484381 | 0.63 | SLC6A3 (0.41) | MEN1KMT2APTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1333836-A4 | CEPHALOSPORIN ANTIBIOTICS AND PRODRUGS THEREOF | ESSENTIAL THERAPEUTICS INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1333836-A2 | CEPHALOSPORIN ANTIBIOTICS AND PRODRUGS THEREOF | Essential Therapeutics, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6599893-B2 | Such as (7R)-7-(2-(2-amino-5-chlorothiazol-4-yl)-2-trityl-oxyiminoacetylamino)-3-(4 -methyl-(1,2, 3)thiadiazol-5-ylsulfanyl)-8-oxo-5-thia-1-aza-bicyclo(4.2.0)oct-2-ene-2 -carboxylic acid benzhydryl ester; methicillin-resistance | ESSENTIAL THERAPEUTICS, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20020115650-A1 | Cephalosporin antibiotics and prodrugs thereof | MICROCIDE PHARMACEUTICALS. | 2002-08-22 | — | — | US | disclosed |
| WO-2002017854-A2 | CEPHALOSPORIN ANTIBIOTICS AND PRODRUGS THEREOF | ESSENTIAL THERAPEUTICS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115650-A1 | Cephalosporin antibiotics and prodrugs thereof | PEPD, ABCG2, ABCC1 | CYP1A2 171/4885GABRA5 2276/4885GABRB2 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.